These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 29317553)

  • 1. Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
    Harbeck N; Gascón P; Krendyukov A; Hoebel N; Gattu S; Blackwell K
    Oncologist; 2018 Apr; 23(4):403-409. PubMed ID: 29317553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K; Gascon P; Krendyukov A; Gattu S; Li Y; Harbeck N
    Ann Oncol; 2018 Jan; 29(1):244-249. PubMed ID: 29091995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
    Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
    Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
    Blackwell K; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Harbeck N
    Ann Oncol; 2017 Sep; 28(9):2272-2277. PubMed ID: 28637287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K; Semiglazov V; Krasnozhon D; Davidenko I; Nelyubina L; Nakov R; Stiegler G; Singh P; Schwebig A; Kramer S; Harbeck N
    Ann Oncol; 2015 Sep; 26(9):1948-1953. PubMed ID: 26122726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
    Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
    BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.
    Tesch H; Ulshöfer T; Vehling-Kaiser U; Ottillinger B; Bulenda D; Turner M
    Oncol Res Treat; 2015; 38(4):146-52. PubMed ID: 25877937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LA-EP2006: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Apr; 33(2):229-232. PubMed ID: 30887256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
    Harbeck N; Lipatov O; Frolova M; Udovitsa D; Topuzov E; Ganea-Motan DE; Nakov R; Singh P; Rudy A; Blackwell K
    Future Oncol; 2016 Jun; 12(11):1359-67. PubMed ID: 27020170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.
    Harbeck N; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Blackwell K
    Future Oncol; 2017 Jul; 13(16):1385-1393. PubMed ID: 28453299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filgrastim biosimilar (EP2006): A review of 15 years' post-approval evidence.
    Gascón P; Harbeck N; Rapoport BL; Anderson R; Brueckmann I; Howe S; Aapro M
    Crit Rev Oncol Hematol; 2024 Apr; 196():104306. PubMed ID: 38401695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
    Botteri E; Krendyukov A; Curigliano G
    Eur J Cancer; 2018 Jan; 89():49-55. PubMed ID: 29227817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
    Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
    J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.
    Gascón P; Krendyukov A; Höbel N; Aapro M
    Eur J Haematol; 2018 Mar; 100(3):241-246. PubMed ID: 29171913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pegfilgrastim biosimilar MD-110 in patients with breast cancer receiving chemotherapy: Single-arm phase III.
    Takano T; Ito M; Kadoya T; Osako T; Aruga T; Masuda N; Miyaki T; Niikura N; Shimizu D; Yokoyama Y; Watanabe M; Tomomitsu M; Aogi K
    Cancer Med; 2023 Oct; 12(20):20242-20250. PubMed ID: 37824431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
    Sagara Y; Sato K; Fukuma E; Higaki K; Mizutani M; Osaki A; Takano T; Tokuda Y; Ohno S; Masuda N; Suzuki M; Saeki T
    Jpn J Clin Oncol; 2013 Sep; 43(9):865-73. PubMed ID: 23858037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
    Park KH; Sohn JH; Lee S; Park JH; Kang SY; Kim HY; Park IH; Park YH; Im YH; Lee HJ; Hong DS; Park S; Shin SH; Kwon HC; Seo JH
    Invest New Drugs; 2013 Oct; 31(5):1300-6. PubMed ID: 23677653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients.
    Hegg R; Mattar A; Matos-Neto JN; Pedrini JL; Aleixo SB; Rocha RO; Cramer-Junior RP; van-Eyll-Rocha S
    Clinics (Sao Paulo); 2016 Oct; 71(10):586-592. PubMed ID: 27759847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.